| Breast Cancer Treatment Studies | Lifetime | 12 | DE 2 | 99.94 |
| Cancer Treatment and Pharmacology | Lifetime | 9 | DE 1 | 99.93 |
| HER2/EGFR in Cancer Research | Lifetime | 14 | DE 2 | 99.91 |
| Advanced Breast Cancer Therapies | Lifetime | 8 | DE 2 | 99.89 |
| Cancer Genomics and Diagnostics | Lifetime | 249 | DE 11 | 99.49 |
| Breast Lesions and Carcinomas | Lifetime | 68 | DE 4 | 99.35 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 258 | DE 11 | 99.36 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 413 | DE 24 | 99.24 |
| BRCA gene mutations in cancer | Lifetime | 174 | DE 5 | 98.52 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 164 | DE 1 | 98.50 |
| Cancer Risks and Factors | Lifetime | 158 | DE 8 | 98.83 |
| Cancer Cells and Metastasis | Lifetime | 453 | DE 32 | 98.04 |
| PARP inhibition in cancer therapy | Lifetime | 166 | DE 13 | 97.68 |
| Multiple and Secondary Primary Cancers | Lifetime | 279 | DE 11 | 97.16 |
| Cancer-related Molecular Pathways | Lifetime | 888 | DE 45 | 97.17 |
| Global Cancer Incidence and Screening | Lifetime | 944 | DE 13 | 96.24 |
| Neutropenia and Cancer Infections | Lifetime | 670 | DE 60 | 94.78 |
| Breast Implant and Reconstruction | Lifetime | 965 | DE 31 | 91.06 |
| Male Breast Health Studies | Lifetime | 224 | DE 14 | 80.57 |
| Breast Cancer Treatment Studies | 2021-2025 | 5 | DE 2 | 99.97 |
| HER2/EGFR in Cancer Research | 2021-2025 | 6 | DE 1 | 99.91 |
| Cancer Treatment and Pharmacology | 2021-2025 | 9 | DE 2 | 99.87 |
| Advanced Breast Cancer Therapies | 2021-2025 | 12 | DE 2 | 99.84 |
| Cancer Genomics and Diagnostics | 2021-2025 | 164 | DE 8 | 98.76 |
| Cancer-related Molecular Pathways | 2021-2025 | 30 | DE 3 | 97.60 |
| BRCA gene mutations in cancer | 2021-2025 | 68 | DE 3 | 97.00 |
| Cancer Risks and Factors | 2021-2025 | 51 | DE 4 | 96.43 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 275 | DE 11 | 95.27 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 925 | DE 31 | 96.41 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 93 | DE 3 | 89.32 |
| Breast Lesions and Carcinomas | 2021-2025 | 171 | DE 19 | 92.13 |
| Cancer Cells and Metastasis | 2021-2025 | 494 | DE 31 | 88.90 |
| PARP inhibition in cancer therapy | 2021-2025 | 278 | DE 12 | 91.59 |
| Estrogen and related hormone effects | 2021-2025 | 527 | DE 14 | 78.89 |
| Male Breast Health Studies | 2021-2025 | 81 | DE 3 | 63.72 |
| TGF-β signaling in diseases | 2021-2025 | 641 | DE 41 | 23.01 |
| Caveolin-1 and cellular processes | 2021-2025 | 517 | DE 30 | 21.01 |
